<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591784</url>
  </required_header>
  <id_info>
    <org_study_id>BT-IST-ESO-002</org_study_id>
    <nct_id>NCT02591784</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer</brief_title>
  <official_title>The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located
      in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
      efficacy has been shown in adult with head and neck cancer. The phase II study assessed the
      efficacy and safety of the combination of Nimotuzumab administered concomitantly with
      radiotherapy in patients with esophageal cancer tumours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical efficacy has been shown in adult with head and neck cancer. The phase II study
      assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly
      with radiotherapy in patients with esophageal cancer tumours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (SD)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disease (PD)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival time (MST)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year,2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Esophageal</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimotuzumab+radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.</description>
    <arm_group_label>Nimotuzumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)</description>
    <arm_group_label>Nimotuzumab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically or cytology diagnosed phase II-III esophageal carcinoma or IV thoracic
             segments carcinoma with the supraclavicular lymph nodes metastasis.

          2. with the measureable lesion of the newly diagnosed the esophageal carcinoma.

          3. age 18-75 years old

          4. ECOG≤2

          5. Expect survival date ≥3 months

          6. without serious diseases of important organs

          7. signature in the inform consent.

        Exclusion Criteria:

          1. pregnant or breast-feeding women or using a prohibited contraceptive method.

          2. with psychiatric diseases.

          3. with serious diseases or uncontrolled infection.

          4. with history of other tumors.

          5. participation other clinical trials within 1 month prior to inclusion in the trial.

          6. not the first antitumor treatment .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lvhua Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Affiliated tumour hosiptal of HARBIN Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute &amp; Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nimotuzumab esophageal radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

